Related Experiment Video
Updated: Jun 8, 2026
04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
Effect of β-adrenergic stimulation on QT interval accommodation
Srikanth Seethala1, Vladimir Shusterman, Samir Saba
1Department of Medicine, Texas Tech University Health Science Center, El Paso, Texas, USA.
Heart Rhythm
|October 19, 2010
Summary
QT interval adaptation to heart rate changes occurs gradually, not instantaneously. Beta-adrenergic stimulation, like dobutamine, alters this response, potentially impacting drug safety assessments.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Background:
- QT interval correction formulas assume instantaneous heart rate (HR) response, yet adaptation is gradual.
- Human QT interval reaches steady-state approximately 2 minutes after HR changes.
Purpose of the Study:
- To investigate the impact of beta-adrenergic stimulation on the QT interval's response to heart rate fluctuations.
- To assess how dobutamine influences the dynamics of QT interval adaptation.
Main Methods:
- Studied 10 subjects undergoing radiofrequency ablation, pacing HR from 60-140 bpm.
- Evaluated QT interval response to sudden HR changes before and during dobutamine infusion (10 μg/kg/min).
Main Results:
- QT adaptation involves an immediate response (IR) and a gradual monoexponential phase (time constant ~1 min).
- Dobutamine reduced steady-state QT, increased IR magnitude (to ~13% of RR change), and elevated QT variability.
- Exponential fit was superior to linear for describing QT adaptation (P < .05).
Conclusions:
- QT interval adaptation exhibits two distinct phases with potentially different mechanisms.
- Beta-adrenergic stimulation may increase QT variability by enhancing the immediate response to HR changes.
- Findings are relevant for assessing drug effects on repolarization and understanding QT variability.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...